Avantor (NYSE:AVTR) (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments. The first, Life Sciences, serves pharmaceutical, biotechnology and academic research institutions with analytical instrumentation, reagents and laboratory supplies for drug discovery, development and quality control. The second, Chemicals & Specialized Services, provides advanced materials, custom chemical synthesis and process technologies to semiconductor, aerospace, electronics and industrial markets.
Founded through the combination of established chemical suppliers dating back to the early 20th century, Avantor adopted its current name in 2011 and has since expanded through strategic acquisitions and organic growth. The company completed its initial public offering in 2019. Avantor is led by President and Chief Executive Officer Michael Stubblefield, who joined the company in 2022 with extensive experience in global manufacturing and technology sectors.
With operations in more than 180 countries, Avantor maintains a network of manufacturing facilities, distribution centers and research support centers across North America, Europe, Asia Pacific and Latin America. The company emphasizes stringent quality standards, regulatory compliance and sustainability initiatives to ensure reliable supply chains and to advance scientific innovation worldwide.
